GLAND PHARMA Financial Statement Analysis
|
||
|
The Revenues of GLAND PHARMA have increased by 56.29% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -9.59 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹5,665 Cr | ₹3,625 Cr | ₹4,401 Cr | ₹3,463 Cr | ₹2,633 Cr |
| Expenses | ₹4,332 Cr | ₹2,600 Cr | ₹2,891 Cr | ₹2,161 Cr | ₹1,678 Cr |
| Operating Profit (Excl OI) | ₹1,333 Cr | ₹1,025 Cr | ₹1,510 Cr | ₹1,302 Cr | ₹955 Cr |
| Other Income | ₹170 Cr | ₹240 Cr | ₹224 Cr | ₹135 Cr | ₹139 Cr |
| Interest | ₹26 Cr | ₹7.45 Cr | ₹5.24 Cr | ₹3.41 Cr | ₹7.18 Cr |
| Depreciation | ₹345 Cr | ₹147 Cr | ₹110 Cr | ₹99 Cr | ₹95 Cr |
| Profit Before Tax | ₹1,133 Cr | ₹1,055 Cr | ₹1,619 Cr | ₹1,335 Cr | ₹993 Cr |
| Profit After Tax | ₹772 Cr | ₹781 Cr | ₹1,212 Cr | ₹997 Cr | ₹773 Cr |
| Consolidated Net Profit | ₹772 Cr | ₹781 Cr | ₹1,212 Cr | ₹997 Cr | ₹773 Cr |
| Earnings Per Share (Rs) | ₹42.40 | ₹46.90 | ₹47.42 | ₹73.75 | ₹60.94 |
| PAT Margin (%) | 12.44 | 13.64 | 21.55 | 27.53 | 28.79 |
| ROE(%) | 7.82 | 9.26 | 10.34 | 18.61 | 20.97 |
| ROCE(%) | 11.97 | 13.63 | 14.04 | 24.85 | 28.00 |
| Total Debt/Equity(x) | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 27,538.9 Cr |
| Revenue (TTM) | : | ₹ 5,801.5 Cr |
| Net Profit(TTM) | : | ₹ 790.4 Cr |
| EPS (TTM) | : | ₹ 48.0 |
| P/E (TTM) | : | 34.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAND PHARMA | 0.1% | -8% | -4.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.9% | -1.8% | -2.5% |
| DIVIS LABORATORIES | 2.1% | 0.2% | 9.1% |
| CIPLA | 0.7% | -0.8% | 3.4% |
| TORRENT PHARMACEUTICALS | 0.5% | 2.2% | 11.2% |
| DR REDDYS LABORATORIES | -0.1% | 2.5% | 2.5% |
| MANKIND PHARMA | 1.5% | -2.8% | -19.5% |
| ZYDUS LIFESCIENCES | -0.2% | -0.8% | -5.7% |
| LUPIN | 1.7% | 4.7% | 3.5% |
GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 56.29 % |
| 5 Yr CAGR | 21.11 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,665 Cr | 56.29 | |
| Mar2024 | ₹3,625 Cr | -17.64 | |
| Mar2023 | ₹4,401 Cr | 27.08 | |
| Mar2022 | ₹3,463 Cr | 31.51 | |
| Mar2021 | ₹2,633 Cr | - | |
GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 30.09 % |
| 5 Yr CAGR | 8.68 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,333 Cr | 30.09 | |
| Mar2024 | ₹1,025 Cr | -32.14 | |
| Mar2023 | ₹1,510 Cr | 15.97 | |
| Mar2022 | ₹1,302 Cr | 36.29 | |
| Mar2021 | ₹955 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -16.77 % |
| 5 Yr CAGR | -10.26 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 23.53% | -16.77 | |
| Mar2024 | 28.27% | -17.63 | |
| Mar2023 | 34.32% | -8.75 | |
| Mar2022 | 37.61% | 3.67 | |
| Mar2021 | 36.28% | - | |
GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -1.10 % |
| 5 Yr CAGR | -0.01 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹772 Cr | -1.10 | |
| Mar2024 | ₹781 Cr | -35.54 | |
| Mar2023 | ₹1,212 Cr | 21.54 | |
| Mar2022 | ₹997 Cr | 29.00 | |
| Mar2021 | ₹773 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -8.80 % |
| 5 Yr CAGR | -18.92 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 12.44 % | -8.80 | |
| Mar2024 | 13.64 % | -36.71 | |
| Mar2023 | 21.55 % | -21.72 | |
| Mar2022 | 27.53 % | -4.38 | |
| Mar2021 | 28.79 % | - | |
GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -9.59 % |
| 5 Yr CAGR | -8.67 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹42 | -9.59 | |
| Mar2024 | ₹47 | -1.10 | |
| Mar2023 | ₹47 | -35.70 | |
| Mar2022 | ₹74 | 21.02 | |
| Mar2021 | ₹61 | - | |
GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -12.18 % |
| 5 Yr CAGR | -19.14 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 11.97% | -12.18 | |
| Mar2024 | 13.63% | -2.92 | |
| Mar2023 | 14.04% | -43.50 | |
| Mar2022 | 24.85% | -11.25 | |
| Mar2021 | 28% | - | |
GLAND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,671.1 |
| Current MarketCap | : | ₹ 27,538.9 Cr |
| Updated EOD on | : | Dec 19,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 0.1% |
-8% |
-4.9% |
| SENSEX | -0.4% |
-0.3% |
3.9% |
GLAND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE MIDCAP | 0.2% | -1.7% | -3.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 50 | 0.2% | -3% | -9.1% |
| NIFTY SMALLCAP 250 | 0.1% | -3.2% | -10.6% |
| NIFTY MNC | 0.1% | -0.1% | 2.4% |
| NIFTY MIDSMALLCAP 400 | NA | -1.9% | -3.2% |
| NIFTY SMALLCAP 100 | NA | -3.8% | -11% |
You may also like the below Video Courses
FAQ about GLAND PHARMA Financials
How the annual revenues of GLAND PHARMA have changed ?
The Revenues of GLAND PHARMA have increased by 56.29% YoY .
How the Earnings per Share (EPS) of GLAND PHARMA have changed?
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -9.59 % YoY .
Check out Intrinsic Value of Peers of GLAND PHARMA
Compare Stock Analytics of Peers of GLAND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
